SAVARA INC
SVRANASDAQTrading Snapshot
- Day Range
- $5.57 – $5.72
- 52-Week Range
- $2.43 – $7.01
- Volume
- $3.36B
- Avg Volume
- $4.44B
- Shares Outstanding
- 204.9M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $81M
- Last Q Revenue
- $22M
- P/E Ratio
- -9.6
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.55
- Dividend Yield
- 0.00%
Why Investors Own SVRA
- ✓High-growth profile — revenue up +27.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 34% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SAVARA INC
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Savara Says MOLBREEVI MAAs Under Review By EMA And U.K's MHRA; Decisions Expected Q1 2027 And Q4 2026, Respectively; European And Australian Patent Offices Grant MOLBREEVI Patents Until March 2041
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at ATS Showed
Savara Q2 EPS $(0.16) Misses $(0.14) Estimate
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump
Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress.